Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group Ltd. (MAYNF)
:MAYNF
Total Valuation
Mayne Pharma Group has a market cap or net worth of $258.37M. The enterprise value is $344.73M.
Market Cap$258.37M
Enterprise Value$344.73M
Share Statistics
Mayne Pharma Group has 81,245,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,245,830
Owned by Insiders0.02%
Owned by Institutions<0.01%
Financial Efficiency
Mayne Pharma Group’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -3.22%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-3.22%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee480.11K
Profits Per Employee-110.40K
Employee Count850
Asset Turnover0.40
Inventory Turnover3.18
Valuation Ratios
The current PE Ratio of Mayne Pharma Group is ―. Mayne Pharma Group’s PEG ratio is 0.09.
PE Ratio―
PS Ratio1.01
PB Ratio1.11
Price to Fair Value1.11
Price to FCF79.25
Price to Operating Cash Flow21.59
PEG Ratio0.09
Income Statement
In the last 12 months, Mayne Pharma Group had revenue of 408.10M and earned -93.84M in profits. Earnings per share was -1.14.
Revenue408.10M
Gross Profit247.27M
Operating Income-23.59M
Pretax Income-83.30M
Net Income-93.84M
EBITDA42.08M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was 17.47M and capital expenditures -12.28M, giving a free cash flow of 5.19M billion.
Operating Cash Flow17.47M
Free Cash Flow5.19M
Free Cash Flow per Share0.06
Dividends & Yields
Mayne Pharma Group pays an annual dividend of $0.378, resulting in a dividend yield of ―
Dividend Per Share$0.378
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change-14.12%
50-Day Moving Average3.44
200-Day Moving Average3.64
Relative Strength Index (RSI)35.79
Average Volume (3m)1.31K
Important Dates
Mayne Pharma Group upcoming earnings date is Feb 19, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend DateJan 18, 2023
Financial Position
Mayne Pharma Group as a current ratio of 1.35, with Debt / Equity ratio of 11.15%
Current Ratio1.35
Quick Ratio1.16
Debt to Market Cap0.09
Net Debt to EBITDA-0.44
Interest Coverage Ratio-4.71
Taxes
In the past 12 months, Mayne Pharma Group has paid 6.78M in taxes.
Income Tax6.78M
Effective Tax Rate-0.08
Enterprise Valuation
Mayne Pharma Group EV to EBITDA ratio is 9.34, with an EV/FCF ratio of 75.68.
EV to Sales0.96
EV to EBITDA9.34
EV to Free Cash Flow75.68
EV to Operating Cash Flow22.50
Balance Sheet
Mayne Pharma Group has $100.40M in cash and marketable securities with $41.27M in debt, giving a net cash position of $59.13M billion.
Cash & Marketable Securities$100.40M
Total Debt$41.27M
Net Cash$59.13M
Net Cash Per Share$0.73
Tangible Book Value Per Share-$2.09
Margins
Gross margin is 60.59%, with operating margin of -5.78%, and net profit margin of -22.99%.
Gross Margin60.59%
Operating Margin-5.78%
Pretax Margin-20.41%
Net Profit Margin-22.99%
EBITDA Margin10.31%
EBIT Margin-5.40%
Analyst Forecast
The average price target for Mayne Pharma Group is $3.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.96
Price Target Upside3.66% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―